Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.

The post Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics appeared first on MedCity News.

Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.

The post VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’ appeared first on MedCity News.

Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year.

The post Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain appeared first on MedCity News.

What matters just as much — if not more — is everything around that number: how customers adopt the product, how sales actually happen, and whether the company is building something that can scale inside a complex, regulated system.

The post Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching Instead appeared first on MedCity News.

Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.

The post Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors appeared first on MedCity News.

Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.

The post Two New Takes on Making a Type of Targeted Cancer Therapy Even Better appeared first on MedCity News.

Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.

The post Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics appeared first on MedCity News.

[Sponsored] By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients. 

The post Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork  appeared first on MedCity News.

Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.

The post Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition appeared first on MedCity News.

Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.

The post Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products appeared first on MedCity News.

Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.

The post Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M appeared first on MedCity News.

Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.

The post Valuing Early-Stage Life Sciences Companies: The Why, the How, and the Impact appeared first on MedCity News.

The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.

The post Startup Atavistik Adds $40M for Clinical Trial in Rare Bleeding Disorder With No Approved Therapies appeared first on MedCity News.

Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential applications in multiple autoimmune disorders. Depending on the progress of Boehringer’s research, Sitryx could receive more than $500 million.

The post Boehringer Boosts Pipeline, Adding Oral Small Molecules With Broad Immunology & Inflammation Potential appeared first on MedCity News.

Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.

The post Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds appeared first on MedCity News.

Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s.

The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News.

Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.

The post Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets appeared first on MedCity News.

Here are some of the structural and strategic causes behind that failure rate, and ways to improve launch outcomes.

The post Addressing the 58% Launch Failure Rate: Accelerating Market Access Through Intelligent Decision-Making appeared first on MedCity News.

[Sponsored] Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.

The post The Hidden Administrative Tasks Draining Small Practices appeared first on MedCity News.

Fortitude Biomedicines is developing antibody drug conjugates that use targeted protein degraders as their therapeutic payloads. The startup joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

The post Startup Fortitude Bio Launches to Beat Drug Resistance in Cancer, Expand ADCs to Autoimmune Disease appeared first on MedCity News.

Innovators who holistically develop their products, studies, and payment strategy with these things in mind will reduce risks, spend less, and reach profitability sooner.

The post The Success Triangle: What MedTech Startups Can’t Ignore appeared first on MedCity News.

Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year.

The post JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabilis, Enodia Emerges & More appeared first on MedCity News.

In today’s dynamic environment, companies are navigating deal-making and innovation spurred by the vertical integration of AI and a rebounding IPO market. Here are ten global trends poised to define the industry in the coming year.

The post 10 Key MedTech Themes for 2026 appeared first on MedCity News.

BioInnovation Institute, which has supported 131 startups in Denmark to date, will use the new funding to expand its reach to startups across Europe. This innovation engine spun out of the Novo Nordisk Foundation in 2020.

The post Novo Nordisk Foundation Commits Up to $850M to Boost European Innovation appeared first on MedCity News.

Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.

The post Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics appeared first on MedCity News.

Check out news from Oral Genome, Beacon Biosignals, Modulight Therapeutics, No Barrier, and Lab Central.

The post StartUPDATES: New Developments for Healthcare Startups appeared first on MedCity News.

Iambic’s latest financing follows the presentation of data for its breast cancer drug during the recent European Society of Medical Oncology conference. Our financing roundup includes capital raised by startups developing novel therapies immunology, metabolic disorders, genetic diseases, and more.

The post Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs appeared first on MedCity News.

Check out news from Oral Genome, Amae Health, Hepta, and more.

The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.

Braveheart Bio is preparing to advance to Phase 3 testing in obstructive hypertrophic cardiomyopathy, or oHCM. The startup says its small molecule could have safety advantages over Camzyos, a Bristol Myers Squibb capsule projected to become a blockbuster seller in this indication.

The post Braveheart Bio Bags $185M for Drug That Could Rival a Bristol Myers Squibb Cardio Med appeared first on MedCity News.

Flagship Pioneering’s newest startup is Expedition Medicines, a company whose artificial intelligence-driven technology platform analyzes the human proteome to learn the chemistry of binding small molecules to protein targets long considered “undruggable.” Expedition already has a cancer drug R&D alliance with Pfizer.

The post Startup Expedition Medicines Launches to Learn Nature’s Rules for Binding Elusive Proteins appeared first on MedCity News.